In 2020, Keith Gottesdiener, M.D. earned $638.44K in total compensation at Rhythm Pharmaceuticals, Inc., primarily from $142.91K salary. Led Rhythm Pharmaceuticals, Inc. as CEO for 2 years.
Compensation History
Annual executive compensation data for Keith Gottesdiener, M.D., including salary, bonuses, and stock awards.
Year
2020
Total Compensation
$638.44K
Salary
$142.91K
Bonus
$0.00
Other
$495.54K
Salary
$142.91KBoard Justification
The compensation philosophy is designed to attract, retain, motivate and reward a highly talented executive team within the context of responsible cost management, linking individual/team performance and results to executive compensation.
Bonus
$0.00Board Justification
Dr. Gottesdiener did not receive a bonus for 2020 performance because he separated from the Company during 2020.
Other Compensation
$495.54KBoard Justification
Includes cash severance payments, cash payments to cover a portion of healthcare expenses following termination, reimbursement of moving expenses, and reimbursement of attorneys’ fees relating to Dr. Gottesdiener’s separation and consulting agreements paid in 2020.
Restricted Stock
Board Justification
No stock awards vested in 2020 as all stock grants were either not vested or not applicable due to separation.
Performance Metrics
Performance metrics were not applicable for Dr. Gottesdiener in 2020 due to his separation from the Company.
Keith Gottesdiener, M.D.
Ex-CEO of Rhythm Pharmaceuticals, Inc.
Education
M.D. from a recognized institution.
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
Born
January 1, 1977 - 48 years ago
CEO of Rhythm Pharmaceuticals, Inc. for
2 years 0 months (Jan 2018 - Jan 2020)
Previous Experience
Various roles at the Company and other organizations in the healthcare space.
Other Rhythm Pharmaceuticals, Inc. CEOs
Holdings
Track Keith Gottesdiener, M.D.'s stock holdings and portfolio value over time.
Insider Trading
Keith Gottesdiener, M.D.'s recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Keith Gottesdiener, M.D. with competitor CEOs and industry peers.